Ninad Dewal
A5079089992- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Endometriosis Research and Treatment
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Genomics and Rare Diseases
- Adrenal and Paraganglionic Tumors
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- Renal cell carcinoma treatment
- PARP inhibition in cancer therapy
- Prostate Cancer Diagnosis and Treatment
- Genomic variations and chromosomal abnormalities
- Genetic Associations and Epidemiology
- Cancer, Lipids, and Metabolism
- CAR-T cell therapy research
- Advanced MRI Techniques and Applications
- Histiocytic Disorders and Treatments
GlaxoSmithKline (United States)
2023
Foundation Medicine (United States)
2017-2020
Baylor College of Medicine
2015-2018
Baylor Genetics
2016
Columbia University
2009-2011
Broad Institute
2009
Case Western Reserve University
2009
Dana-Farber Cancer Institute
2009
As availability of precision therapies expands, a well-validated circulating cell-free DNA (cfDNA)-based comprehensive genomic profiling assay has the potential to provide considerable value as complement tissue-based testing ensure potentially life-extending are administered patients most likely benefit. Additional data supporting clinical validity cfDNA-based is necessary inform optimal use these assays in clinic. The FoundationOne®Liquid CDx pan-cancer that was recently approved by FDA....
FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) technology examine 324 cancer genes solid tumors. reports known likely pathogenic short variants (SVs), copy number alterations (CNAs), select...
Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor.
Abstract The genomic and clinical information used to develop implement therapeutic approaches for acute myelogenous leukemia (AML) originated primarily from adult patients has been generalized with pediatric AML. However, age-specific molecular alterations are becoming more evident may signify the need age-stratify treatment regimens. NCI/COG TARGET-AML initiative whole exome capture sequencing (WXS) interrogate landscape of matched trios representing specimens collected upon diagnosis,...
PURPOSE Comprehensive genomic profiling (CGP) is increasingly used for routine clinical management of prostate cancer. To inform targeted treatment strategies, 3,476 clinically advanced tumors were analyzed by CGP alterations (GAs) and signatures instability. METHODS Prostate cancer samples (1,660 primary site 1,816 metastatic from unmatched patients) prospectively (FoundationOne Assay; Foundation Medicine, Cambridge, MA) GAs (genome-wide loss heterozygosity [gLOH], microsatellite...
The ampulla of Vater is a complex cellular environment from which adenocarcinomas arise to form group histopathologically heterogenous tumors. To evaluate the molecular features these tumors, 98 ampullary were evaluated and compared 44 distal bile duct 18 duodenal adenocarcinomas. Genomic analyses revealed mutations in WNT signaling pathway among half patients all three irrespective their origin histological morphology. These tumors characterized by high frequency inactivating ELF3, rate...
Abstract Purpose: This interim report of the GARNET phase I trial presents efficacy and safety dostarlimab in patients with advanced or recurrent endometrial cancer (EC), an analysis tumor biomarkers as prognostic indicators. Patients Methods: A total 153 mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) 161 proficient (MMRp)/microsatellite stable (MSS) EC were enrolled dosed. received 500 mg every 3 weeks for four cycles, then 1,000 6 until progression. Primary...
Cancer is a disease driven by combination of inherited risk alleles coupled with the acquisition somatic mutations, including amplification and deletion genomic DNA. Potential relationships between aspects have only rarely been examined on genome-wide level. Applying novel integrative analysis SNP copy number measurements, we queried tumor normal-tissue genomes 178 glioblastoma patients from Genome Atlas project for preferentially amplified alleles, under hypothesis that oncogenic germline...
During tumor initiation and progression, cancer cells acquire a selective advantage, allowing them to outcompete their normal counterparts. Identification of the genetic changes that underlie these acquired traits can provide deeper insights into biology tumorigenesis. Regions copy number alterations germline DNA variants are some elements subject selection during evolution. Integrated examination inherited variation somatic holds potential reveal specific nucleotide alleles “prefers” have...
e13685 Background: As the availability of precision therapies expand, a well-validated blood-based comprehensive genomic profiling (CGP) assay has potential to provide considerable value as complement tissue-based testing ensure that potentially life-extending are administered patients most likely benefit. Comprehensive clinical and analytical validity data for assays crucial enabling physicians understand true performance available options. Methods: The FoundationOne Liquid CDx is CGP been...
Abstract Motivation: Somatic amplification of particular genomic regions and selection cellular lineages with such amplifications drives tumor development. However, pinpointing genes under has been difficult due to the large span these regions. Our recently-developed method, distortion test (ADT), identifies specific nucleotide alleles haplotypes that confer better survival for cells when somatically amplified. In this work, we focus on evaluating ADT's power detect causal variants across a...
Coronary computed tomographic angiography (CCTA) with prospective electrocardiographic gating reduces radiation exposure, but its prognostic power for predicting cardiovascular risk in patients suspected CAD has not been fully validated. To determine whether performs as well retrospective this population, we compared these scan modes undergoing 64-slice CCTA. From January 2009 through September 2011, 1,407 underwent CCTA; of these, 915 (mean age, 57.8 ± 13.5 yr; 54% male) had coronary artery...
<p>This includes supplementary tables and figures</p>
<div>Abstract<p>Purpose: This interim report of the GARNET phase I trial presents efficacy and safety dostarlimab in patients with advanced or recurrent endometrial cancer (EC), an analysis tumor biomarkers as prognostic indicators. Patients Methods: A total 153 mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) 161 proficient (MMRp)/microsatellite stable (MSS) EC were enrolled dosed. received 500 mg every 3 weeks for 4 cycles, then 1000 6 until progression....
<p>This includes supplementary tables and figures</p>
Abstract Adrenocortical carcinoma (ACC) is a rare neoplasm with heterogeneous outcome and limited treatment options. To understand its molecular genomic landscape as part of The Cancer Genome Atlas (TCGA) project, we performed the genomic, transcriptomic, epigenomic proteomic profiling 91 ACCs. We identified potential driving alterations including amplifications (TERT, TERF2 CDK4), deletions (ZNRF3, CDKN2A RB1) point mutations in genes unknown to participate adrenal disease (RPL22) known...
<div>Abstract<p>Purpose: This interim report of the GARNET phase I trial presents efficacy and safety dostarlimab in patients with advanced or recurrent endometrial cancer (EC), an analysis tumor biomarkers as prognostic indicators. Patients Methods: A total 153 mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) 161 proficient (MMRp)/microsatellite stable (MSS) EC were enrolled dosed. received 500 mg every 3 weeks for 4 cycles, then 1000 6 until progression....
Abstract Introduction: Increase in targeted therapies has resulted the need for a single assay capable of detecting diverse biomarkers indicated these agents. Comprehensive genomic profiling (CGP) provides such solution, but due to complexity and number assays available today, standardization validation become critically important. We present FoundationOne CDx, first NGS-based comprehensive companion diagnostics (CDx) platform developed performed compliance with FDA 21 CFR part 820. The...